Neuronal microtubules support intracellular transport, facilitate axon growth, and form a basis for neuronal morphology. While microtubules in nonneuronal cells are depolymerized by cold, Ca 2+ , or antimitotic drugs, neuronal microtubules are unusually stable. Such stability is important for normal axon growth and maintenance, while hyperstability may compromise neuronal function in aging and degeneration. Though mechanisms for stability are unclear, studies suggest that stable microtubules contain biochemically distinct tubulins that are more basic than conventional tubulins. Transglutaminase-catalyzed posttranslational incorporation of polyamines is one of the few modifications of intracellular proteins that add positive charges. Here we show that neuronal tubulin can be polyaminated by transglutaminase. Endogenous brain transglutaminase-catalyzed polyaminated tubulins have the biochemical characteristics of neuronal stable microtubules. Inhibiting polyamine synthesis or transglutaminase activity significantly decreases microtubule stability in vitro and in vivo. Together, these findings suggest that transglutaminase-catalyzed polyamination of tubulins stabilizes microtubules essential for unique neuronal structures and functions.
INTRODUCTION
Neuronal microtubules (MTs) are biochemically and physiologically diverse. Multiple genes for a-and b-tubulins are expressed differentially during development and regeneration. Tubulins are also subject to posttranslational modifications, and contain a heterogeneous group of microtubule-associated proteins (MAPs) (Ludueñ a, 1998) . The functional consequences of such diversity are thought to be generating MTs suited for unique demands of cells. Neurons are unusually polarized, with a single long axon and multiple branching dendrites. MTs in axons may be very long (more than hundreds of microns in axons), and axonal MTs are maintained for weeks or months at considerable distances from sites of tubulin synthesis (>1 m in some human nerves), imposing unusual constraints on neuronal MTs. Unlike MTs in nonneuronal cells, which can be highly dynamic (Desai and Mitchison, 1997) , axonal MTs are more stable, allowing them to act as a structural framework for the neuron, serve as tracks for organelle transport, maintain cell shape and connections, and define functional compartments (Brady, 1993) . Moreover, MTs in axons are not continuous with a perikaryal microtubule organizing center or visible nucleating structure (Yu and Baas, 1994) . How can axonal MTs extend for such distances and be stable for so long, yet retain the ability to be modified in response to physiological stimuli? A simple answer would be the presence of a significant fraction of stable MTs. This stable MT fraction is important not only for cytoskeletal organization in early neuronal development (Kirkpatrick and Brady, 1994; Kirkpatrick et al., 2001 ) and axon maintenance through adulthood, but also for structural rearrangement for axon regrowth and targeting during regeneration (Brady, 1993) . More interestingly, the increases in MT stability correlate with decreases in neuronal plasticity, and both occur during aging and in some neurodegenerative diseases. Therefore, learning about stable MT fragments, which are unique to neurons, is crucial for understanding normal axonal development and neuronal differentiation; this may also aid in identifying novel therapeutic targets for neurodegeneration and regeneration.
The existence of a stable, biochemically distinct fraction of axonal tubulin was demonstrated some years ago (Brady et al., 1984; Sahenk and Brady, 1987) . When preparing MTs from brain extracts, a substantial amount of tubulin remains in the pellet following low-temperature depolymerization. This fraction is termed cold-insoluble, or cold-stable tubulin. A more extensive differential extraction using cold and Ca 2+ extractions to produce labile, cold-stable, and cold/Ca 2+ -stable fractions was developed ( Figure 1A ). The cold/Ca 2+ fraction was enriched in axons. Using axonal transport to metabolically label MTs in rat optic nerve, the cold/Ca 2+ -stable tubulin fraction (P2) was examined by 2D-PAGE. A striking difference was found between tubulins in soluble and those in stable MTs: some tubulins in P2 exhibited a significant basic shift during isoelectric focusing (IEF) (Brady et al., 1984) . This suggested that tubulins in stable MTs were biochemically distinct from those in cold-labile MTs. Specifically, cold-stable MTs contained tubulins significantly more basic than predicted from sequence or observed in coldcycled MTs.
Stability of MTs has been related to differences in MAPs, specific tubulin isotypes, and posttranslational modifications, but no factor has been identified that is sufficient to make MTs stable to depolymerization by cold or elevated Ca 2+ . MAPs stabilize cycled MTs in vitro (Chapin and Bulinski, 1992) , but the increase in stability is modest and MAPs partition with both stable and labile MTs (Brady et al., 1984) . Similarly, detyrosination and acetylation of a-tubulin correlate with MT stability in many systems (Bulinski et al., 1988) , but in vitro these modifications confer no measurable change in MT stability (Maruta et al., 1986; Webster et al., 1990) and are found in all cell types. Specific tubulin isotypes may contribute to MT stability (Falconer et al., 1994) , but none partitions specifically with stable MTs, and again, differences in stability are modest. The native pI values for highly conserved tubulin isoforms all fall within a narrow range (pI = 5.5-5.6 for mouse a-tubulins, pI = 4.8-4.9 for mouse b2-6 tubulins and pI = 5.6 for b1 tubulin). MAPs do not associate with tubulin in IEF gels or change the charge on tubulins. Thus, no known tubulin isotype or modification can account for both the basic shift and exceptional stability of P2 tubulins, suggesting a novel posttranslational modification.
The unusual IEF behavior of tubulin in cold-stable fractions suggests the addition of a positive charge to affected subunits, but most familiar modifications of cytoplasmic proteins are acidic or neutral, including phosphorylation, acetylation, detyrosination, and glycosylation. One exception is covalent addition of a polyamine, such as putrescine (PUT), spermidine (SPD), or spermine (SPM), to a protein-bound glutamine residue by a transglutaminase (Mehta et al., 2006) . Polyamines are abundant multivalent cations in many tissues, present at high levels in brain (Slotkin and Bartolome, 1986) . Polyaminated proteins may exhibit unusual stability, increased insolubility, and resistance to proteolysis (Esposito and Caputo, 2005) . Ambron found that radioactive polyamines were covalently linked to various neuronal proteins in Aplysia, including a putative tubulin (Ambron and Kremzner, 1982) . Polyamines and transglutaminase are abundant in brain, but their physiological roles in neurons are not well defined. However, increases in transglutaminase activity and polyamine levels correlate with neuronal differentiation and neurite outgrowth (Maccioni and Seeds, 1986; Slotkin and Bartolome, 1986) .
The properties of polyamines and transglutaminase are consistent with polyamination playing a role in stabilizing MTs. We tested the hypothesis that polyamination of axonal tubulins leads to generation of cold-stable MTs. When endogenous polyamine levels were lowered in rats using an irreversible inhibitor of polyamine synthesis, cold-stable tubulin levels significantly decreased. Both in vivo labeling of tubulin with radioactive PUT and in vitro transamidation with monodansylcadaverine (MDC, a fluorescent diamine) indicated that neuronal tubulin is a substrate for polyamination by transglutaminase. Polyamine modification sites were mapped by liquid chromatographytandem mass spectroscopy (LC-MS/MS) and were consistent with sequence-specific incorporation of polyamines into neuronal tubulins by transglutaminase. MTs containing transglutaminase-catalyzed polyaminated tubulins were resistant to cold/Ca 2+ depolymerization and had added positive charge, mimicking neuronal stable MTs, which are largely restricted to nervous tissues and highly enriched in axons in vivo. Further, a mouse model in which the major brain transglutaminase isoform 2 (TG2) was knocked out had decreased neuronal MT stability. Finally, TG2 was identified as playing a role in stabilizing MTs in mouse brains at different postnatal times as neurons mature and myelination of axons progresses. Transglutaminase-catalyzed polyamination of tubulin was essential for neurite growth and neuronal differentiation, as well as MT stability in culture. control or DFMO-treated rats (7 days pretreatment). Tubulin and neurofilament triplet proteins are the major labeled protein species in the P2 fraction of control nerves. Tubulin consistently shifted from P2 to S1 with DFMO treatment, whereas neurofilaments remained in P2.
(C) Compared with control, DFMO treatments for both 7 and 21 days significantly decreased stable tubulin levels without affecting neurofilament fractionation (see Table S1 ). Statistical analysis was by Student's t test. **p < 0.001. Error bars indicate ±SEM. See also Table S1 and Figure S1 .
Together, these results indicated that transglutaminase-catalyzed polyamination of neuronal tubulins contributes to MT stability in axons and this posttranslational modification is important for neuronal development and maturation.
RESULTS

Inhibition of Polyamine Synthesis Significantly Decreases Axonal MT Stability
To determine whether polyamines are needed for cold/Ca 2+ -stable tubulin (CST), endogenous polyamine levels were lowered and CST evaluated in rat optic nerve. The rate-limiting enzyme in polyamine biosynthesis is ornithine decarboxylase (ODC) (Pegg and McCann, 1988) . Difluoromethylornithine (DFMO) is a suicide inhibitor of ODC. Administered to rats as a 2% solution in drinking water, DFMO lowers total polyamine levels significantly in all tissues examined (Danzin et al., 1979) . Rats treated with DFMO for 2-21 days were used to determine the effects of reduced neuronal polyamine on CST. After 18 hr, 7 days, and 21 days of treatment, axonal MTs were labeled by injecting 35 S-methionine into the vitreous of the eye and waiting 21 days for axonal transport to deliver labeled tubulin to the optic nerve. Cold/Ca 2+ fractionation of labeled optic nerve ( Figure 1A ) showed a significant decrease in CST after DFMO treatment ( Figures 1B and 1C) . Fluorographs of S1, S2, and P2 fractions from control and DFMO-treated rats show a significant fraction of tubulin shifted from P2 to S1 fractions with DFMO treatment ( Figure 1B) . In control optic nerves, 52% of the total radiolabeled axonal tubulin was cold-insoluble tubulin, but in 7 day or 21 day DFMO-treated nerves, this fraction was <40% ( Figure 1C ; see also Figure S1 available online; Table S1) (p < 0.001), suggesting that polyamines are required for generation of cold-insoluble tubulin in axons. To determine whether a decrease in polyamines generally reduced cytoskeleton stability in axons or was specific for MTs, neurofilament (NFM) fractionation was analyzed in parallel. There was no change in NFM fractionation after DFMO treatment (Table S1 ).
In Vivo Labeling of Tubulin with Radiolabeled Polyamines Next, we sought to determine whether polyamines were covalently added to tubulin in vivo and whether modified tubulin cofractionated with cold-insoluble tubulin.
14 C-PUT axonal transport labeling experiments were performed in rat optic nerves. Due to high levels of endogenous polyamines and low specific activity of 14 C-PUT, endogenous polyamine levels were lowered by 18 hr DFMO pretreatment. When axonal proteins were fractionated 21 days after 14 C-PUT labeling, 70%-80% of the label was in P2 (not shown). Subsequent fractionation studies with higher-specific-activity 3 H-PUT confirmed these results ( Figure 2A ). In optic nerves labeled by axonal transport of 3 H-PUT, the only proteins with significant incorporation of labeled polyamines had the molecular weight (MW) of tubulin, although 35 S-methionine labeled neurofilaments at the same time. Much lower levels of 3 H-PUT were seen in S1, the coldlabile MT fraction. This suggested that polyamination of tubulin can occur before formation of stable MTs. Polyaminated tubulin may help nucleate and stimulate polymerization of tubulins and may also stabilize MTs after polymerization. 14 C-PUT-labeled proteins in P2 were analyzed by gel filtration chromatography on a Toyopearl HW-55F (Supelco) column equilibrated in 6 M guanidine-HCl in MES to determine if 14 C-PUT coeluted with tubulin. A single broad peak of 14 C eluted 20-30 ml after the void volume coinciding with the peak of tubulin immunoreactivity. There was no peak of 14 C corresponding to free polyamines ( Figure 2B ), suggesting that polyamines in CST fractions were covalently incorporated into axonal tubulins.
Polyamination of Neuronal Tubulins and MTs In Vitro
In vivo stabilization of neuronal MTs by polyamines could occur by covalent posttranslational modification of tubulins. To confirm modification of tubulins with polyamines and evaluate a potential role for transglutaminase, an enzyme known to catalyze polyamination, purified mouse brain tubulin/MTs were incubated with recombinant transglutaminase in vitro. In vitro transglutaminase activity was controlled by addition of Ca
2+
. Transglutaminase polyaminated both tubulin and polymerized MTs via a Ca 2+ -dependent reaction. Modification was visualized in two ways: First, MDC, a fluorescent diamine and transglutaminase substrate (Lorand et al., 1971) , was used as a polyamine analog, giving a fluorescent band at the apparent MW of tubulin in SDS-PAGE. This band was observed whether the substrate Figure 3A ; see also Figure S2 ). Second, modified tubulins were visualized by immunoblot when physiological polyamines (SPM and SPD) were used. Bands were identified as tubulin using the DM1A antibody against a-tubulin, and polyamine modification was identified with an anti-SPM/SPD antibody that recognizes both SPM and SPD ( Figure 3B ). Both free tubulin and tubulin in MTs were modified by transglutaminase and SPM/SPD. Polyaminated tubulins/MTs showed reduced solubility as the bulk of modified tubulins were pelleted. When transglutaminase was incubated with tubulin without polyamines, we observed tubulin crosslinking, but crosslinked tubulin aggregates remained in supernatants rather than pelleting, and much crosslinked tubulin failed to enter the gel ( Figures 3C and 3D) . The presence of polyamines in reactions largely eliminated crosslinking. To determine whether modification of tubulin by transglutaminase favors disassembled or polymerized tubulin, similar amounts of free tubulins and taxol-stabilized MTs were incubated in vitro with transglutaminase and polyamines. There was no significant difference in incorporation of either MDC (Figures 3C and 3D) or SPM/SPD (data not shown). Patterns of polyamine modification on unassembled tubulins ( Figures 3A-3D ), polymerized MTs ( Figure 3A) , and taxol-stabilized polymerized MTs ( Figures 3C and 3D ) were similar. Electron microscopy showed polyaminated tubulins polymerized in vitro at 37 C (Figure 3E ). In contrast, tubulin treated with transglutaminase without polyamines formed large aggregates with no evidence of MT formation ( Figure 3F ). Since intracellular polyamine levels are high, crosslinking is unlikely to occur. These data suggest that transglutaminase-catalyzed polyamination of tubulin occurs on both tubulin and MTs, and that polyaminated tubulins polymerize normally. (B) SPM and SPD were also incorporated into neuronal tubulin. Immunoblotting for polyamine (red) and tubulin (green) showed polyaminated tubulins in yellow (merge) (also see Figure S2 ). Neuronal MTs polymerized in vitro showed comparable tubulin modifications (not shown).
(C) gpTgase-catalyzed covalent addition of MDC was comparable for tubulin and taxol-stabilized MTs. Polyaminated proteins showed decreased solubility and were enriched in pellets.
(D) Coomassie-blue-stained gel (left) showed similar amounts of tubulin and taxol-stabilized MTs as substrates for polyamination in (C). In the absence of polyamines, transglutaminase catalyzed crosslinking of tubulins (right), but crosslinked tubulins were primarily in supernatants and could not enter the stacking gel (not shown).
(E) Negative-stain electron microscopy (EM) showed polymerized MTs with polyaminated tubulin. Several different magnification images show that many MTs are present in this fraction.
(F) Negative-stain EM showed crosslinked tubulin aggregates by transglutaminase in the absence of polyamines.
Identification of Polyamination Sites on Neuronal Tubulins
To verify covalent modification of tubulin and map modification sites, purified mouse brain tubulin/MTs modified in vitro by transglutaminase were analyzed by LC-MS-MS. In independent experiments, four different polyamines or analogs (PUT, SPD, SPM, and DMC) all modified tubulin in vitro in a similar way, as identified by LC-MS-MS ( Figure 4 ). Similar results were observed with tubulin from P2 cold/Ca 2+ -stable MTs in vivo ( Figures S3A and S3B). LC-MS-MS analysis of tubulin from S1 cold-labile MTs failed to detect significant amounts of polyamine-modified tubulins. Putative modification sites on both a-and b-tubulins were mapped by MS1 spectra based on mass shift (Figures 4A and 4B) . Selective modification sites were not sensitive to specific polyamines used in vitro but did depend on the amino acid sequence. Putative modification sites were confirmed by MS/MS, based on specific ion shifts (Figures 4B-4E; see also Figure S3C ) and locations predicted relative to tubulin dimer structure (Figures 4F and S3D) . Conserved sites were identified in multiple tubulin isoforms. Targeted MS/MS analysis verified that the Q at position 13 of a conserved N terminus b-tubulin tryptic peptide EIVHIQAGQCGNQIGAK (corresponding to the highly conserved Q15 in the b-tubulin sequence) was a primary modification site ( Figure 4A ). Q15 is present in all mouse and human b-tubulin sequences ( Figure S3C ). Based on a predicted tubulin dimer structure (Nogales et al., 1998) , the Q15 residue is adjacent to the hydrolyzable GTP in b-tubulin, allowing interaction between polyamines and GTP, where it might affect GTP binding and/or hydrolysis. Additional conserved sites were identified, including sites on both a-and b-tubulins (data not shown).
Modified residues on a-tubulins (Q31, Q128, Q133, Q256, and Q285) were of particular interest, because they were on the surface between a-tubulin and b-tubulin in adjacent dimers. Identification of modification sites in the interface between a-and b-tubulin is consistent with the theory that polyamine modification plays a role in MT stabilization.
Biochemical Characteristics of Polyaminated Brain Tubulins Catalyzed by Endogenous Transglutaminase
To determine whether neuronal transglutaminase and endogenous polyamines were sufficient to modify tubulins, we prepared a crude extract of endogenous transglutaminase from fresh 1 month mouse brains ( Figure S4 ). Figure 6A ). Stable tubulin in testes may be associated with flagellar MTs and the role of polyaminated tubulin there remains to be determined. Transglutaminase activity in brain results from multiple gene products, including TG1, TG2, TG3 (Kim et al., 1999) , and TG6 (Hadjivassiliou et al., 2008) , but the primary cytoplasmic transglutaminase in brain is thought to be TG2 (Bailey and Johnson, 2004) . To understand the role of TG2 in producing CST, we analyzed TG2 protein and enzymatic activity in brain gray matter enriched in perikarya/dendrites (cerebral cortex, brain stem, and spinal cord) and in white matter enriched in axons (optic and sciatic nerves). CST levels were significantly higher (>50% of total tubulin) in adult optic nerves than in cerebrum, which is enriched in dendrites and perikarya. Axonal enrichment of CST suggested a spatial correlation between transglutaminase activity and CST levels. Transglutaminase activity was elevated in both optic and sciatic nerves ( Figures 6B and 6C ), consistent with TG2 immunoreactivity (Figures 6D and 6E ). Sciatic nerve had less TG2 immunoreactivity than optic nerve ( Figures 6D  and 6E ), but sciatic nerve transglutaminase enzyme activity was equivalent to that of the optic nerve ( Figures 6B and 6C) , suggesting differential expression of transglutaminase isoforms in CNS and PNS. Quantification of TG2 protein in axonal tracts was normalized to actin, which is enriched in optic and sciatic nerve relative to cerebral cortex, brain stem, and spinal cord, so relative TG2 levels in optic/sciatic nerves (Figures 6D and 6E) are not directly comparable to other brain regions, but good spatial correlation existed between transglutaminase activity and CST distribution in nervous tissues.
Inhibition of Transglutaminase Activity Inhibited Neurite Growth
Since MT stability is essential for neuronal structure and function, transglutaminase-catalyzed polyamination of tubulin may affect neuronal morphology. To test this, SH-SY5Y neuroblastoma cells were differentiated by retinoic acid and BDNF in the presence of 10 mM IR072 ( Figure S5 ), an irreversible transglutaminase inhibitor. Both transglutaminase activity and TG2 protein level were upregulated as cells differentiated and extended neurites (data not shown), correlating with increased MT stability (Figure 7 ). Inhibition of transglutaminase had a significant effect on SH-SY5Y morphology ( Figure 7B ) compared with cells treated with vehicle ( Figure 7A ). IR072-treated cells remained viable but no longer proliferated, although they showed a phenotype more like that of undifferentiated SH-SY5Y cells. Average neurite length was severely reduced from 76 mm in control cells to 29 mm with IR072 ( Figures 7C and 7D ). Some control SH-SY5Y cells put out extremely long neurites (>150 mm), but Figure 7E ). These suggested that transglutaminase is essential for early neurite development by generating stable tubulin/MTs and possibly by enhancing MT polymerization.
Altered CST Formation in a TG2-KO Mouse
Our data suggested a direct role for TG2 in CST formation in the CNS. To test this, we evaluated CST levels in brain and spinal (C and D) Chromatograms confirmed the presence of PUT-P EIVH in brain stable MT fraction (P8), suggesting that the same modification occurs in vivo and that the modification is sequence specific. Detailed modification patterns on the precursor and its ion series were shown in (D); peaks corresponding to SPM-modified peptide (SPM-P EIVH ) were observed in the same fractions. (E) A summary of peak areas for polyaminated P EIVH from mouse brain MT fractions showed significantly higher levels of PUT-P EIVH and SPM-P EIVH in stable MT fractions (P) compared with labile MT fractions (S). (F) Putative polyaminated sites on tubulins were shown in terms of the protein structure. Using coordinates from the Protein Structure database (MMDB ID, 8900; Protein Data Bank ID, 1TUB) for predicted structures for taxotere-bound tubulin dimer (Nogales et al., 1998) , the conserved Q15 residue is located adjacent to phosphates on the exchangeable GTP in b-tubulin. The structure was generated using Cn3D software (National Library of Medicine). This location suggests that positively charged polyamines might stabilize GTP and affect hydrolysis, consistent with a role for polyamines in modulating microtubule dynamics. Circles are superimposed at Q15 to illustrate approximate dimensions of putrescine (red dashed circle) and spermine (gray circle). Note the potential for interacting with b-tubulin GTP. See also Figure S3 and Tables S2, S3 , and S4. Figure S2 ).
cord of TG2-KO mice (Nanda et al., 2001) , where no TG2 immunoreactivity was detectable ( Figure 8A , upper band). Total transglutaminase enzymatic activity was reduced to <30% of wild-type (WT) in both brain and spinal cord ( Figure 8B and 8C). Although transglutaminase activity and TG2 protein levels were comparable in brains of 5 week and 5 month WT mice, transglutaminase activity and TG2 protein levels decreased significantly in 5 month WT spinal cord relative to the corresponding levels in 5 week WT spinal cord. CST levels ( Figures 8D and 8E , black bars) and cold/ Ca 2+ -stable tubulin levels ( Figures 8D and 8E , white bars) correlated with transglutaminase activity/TG2 protein levels in brain. CST levels were drastically reduced in 5 week TG2 KO mouse brain and spinal cord relative to the levels in age-matched WT mice. The drop remained in 5 month TG2 KO brain, but CST and transglutaminase activity levels in 5 month TG2 KO spinal cord were comparable to those seen in age-matched WTs, where TG2 protein level is low. Compensation from other transglutaminase isoforms (mainly TG1 and TG3) in brain maintained some transglutaminase activity, and CST remains sufficient to maintain the fundamental structure and function of the CNS in this model. Future experiments knocking down other isoforms to reduce further total transglutaminase activity will be needed to see the phenotype due to complete elimination of transglutaminase and CST.
Upregulation of TG2 and CST during Brain Development Increases in TG2 levels and activity between 5 weeks and 5 months of age (Figure 8 ) suggested that TG2 and stable MTs play a role in neuronal maturation. Earlier studies indicated that microtubule stability increased with axonal maturation and myelination (Kirkpatrick and Brady, 1994) , 2 weeks postnatal in mouse. To test whether stabilization of axonal MTs during this stage correlates with transglutaminase-catalyzed polyamination of neuronal tubulin, we examined transglutaminase activity and TG2 immunoreactivity in one hemisphere of mouse brains at 10 days, 3 weeks, and 3 months ( Figures 9A-9D ). Cold/Ca 2+ fractionations were performed on the other hemisphere ( Figure 9E ). Both transglutaminase activity ( Figures 9A and 9B ) and TG2 immunoreactivity ( Figures 9C and 9D ) were low in 10 day brains, increased to a similar extent in 3 week brains, and continued to increase in 3 month brains. Correspondingly, cold-stable and cold/Ca 2+ -stable tubulin levels rise concurrently ( Figure 9E ), indicating a strong temporal and developmental correlation between transglutaminase activity, TG2 expression, and MT stability in postnatal development of mouse brain. The result may be to stabilize microtubules in vivo during axon maturation and later stages of life, a process different from initiation and stabilization of early neurite development.
DISCUSSION
Regulation of MT polymer dynamics remains an important topic of study (Kueh and Mitchison, 2009 ). MTs are generally quite dynamic in nonneuronal cells, consistent with their need to rapidly reorganize during division or migration (Desai and Mitchison, 1997) . In contrast, neurons must balance two opposing properties of MTs: stability and dynamics. Stability is needed for axonal MTs to provide a structural framework and serve as tracks for axonal transport, while dynamics are needed for reorganization and repair during neurite growth and remodeling of synaptic connections (Brady, 1993) . Most MTs remain intact for long periods of time in axons that may be >1 m long in humans.
Consistent with the idea of increased stability of axonal MTs, a large fraction of neuronal tubulin pellets after extraction with cold, Ca 2+ , or antimitotic drugs: treatments that depolymerize most nonneuronal MTs. The morphological correlate of insoluble tubulin is stable segments of MTs (Sahenk and Brady, 1987) that are enriched in axons, continuous with labile MT polymer, and may serve as nucleation sites for adding tubulin dimers to MTs (Brady et al., 1984; Sahenk and Brady, 1987) . Stable MTs provide a stable structural framework for neurons while acting as axonal MT organizing centers to facilitate remodeling of MTs -stable tubulin was enriched in brain but was at or below levels of detection in nonneuronal tissues other than testes. The stable tubulin fraction in testes is presumably due to the stable microtubules in sperm flagella and may not be equivalent to the brain fraction. However, polyamines and TG2 are present in testes. (B) Transglutaminase activity was present in various neural tissues, including cerebral cortex (CC), brain stem (BS), spinal cord (SC), optic nerve (ON), and sciatic nerve (SN) from 5-week-old mice. (C) Quantitative plots showed that transglutaminase activity higher in axon-enriched compartments, like ON and SN, correlated with higher MT stability in axons. (D) TG2 protein was also expressed differentially in various neural tissues. The same amount of total protein was loaded in each lane. Actin and GAPDH were loading controls. Actin was higher in axon-rich domains (ON and SN), while GAPDH was lower in axon-rich tissues as a fraction of total protein.
(E) Quantitative comparison shows that the TG2/ actin ratio was lower in SN than in ON, but SN exhibited comparable levels of TG activity (C); thus, other transglutaminase isoforms may contribute to axonal transglutaminase activity, particularly in the PNS. Statistical analysis was by Student's t test. **p < 0.001. Error bars indicate ±SEM.
after stimulation or injury. However, the molecular basis for generation of this fraction was poorly understood and not explained by previously characterized tubulin modifications.
Stable axonal MTs have been isolated and characterized, as reported in the literature (Brady et al., 1984) . Tubulin in these fractions is notable in two ways: (1) stable MTs are biochemically distinct from cold-labile MTs; and (2) levels of axonally transported cold-insoluble tubulin correlate with axonal plasticity and maturation. Stable MTs comprise a higher fraction of axonal MTs than of nonaxonal MTs (dendrites and perikarya). Myelindeficient axons contain lower levels of CST (Kirkpatrick and Brady, 1994; Kirkpatrick et al., 2001) , and young neurons contain lower levels of CST than do older neurons (Brady and Black, 1986; Kirkpatrick and Brady, 1994; Kirkpatrick et al., 2001) . These data suggest that cold-stable MTs play a role in neuronal maturation, making the biochemical basis of MT cold stability a subject of much interest.
Analysis of purified stable MTs by 2D-PAGE revealed a striking difference between tubulins in labile and those in stable fractions: a shift in pI suggested that some tubulins in the stable fraction were more basic than predicted by primary sequence, consistent with the addition of positive charge. Most familiar posttranslational modifications of tubulins in brain were acidic (phosphorylation and glutamylation) or charge neutral (acetylation and detyrosination) (Janke and Kneussel, 2010) . The positive charge implied a novel modification of tubulins.
A modification that adds positive charge to proteins is covalent addition of polyamines by transglutaminase. Consistent with this, a 56-kDa protein in Aplysia neurons was polyaminated (Ambron and Kremzner, 1982) . Given that polyaminated proteins may be less soluble, polyamination of tubulins might explain cold insolubility. The abundance of polyamines in postmitotic neurons (Slotkin and Bartolome, 1986 ) and the presence of significant transglutaminase activity in brain (De Vivo et al., 2009) were consistent with this idea.
Polyamine levels are high in developing and adult nervous systems (Shaw and Pateman, 1973) , and they affect neuron migration, axon outgrowth, and synapse formation (Slotkin and Bartolome, 1986 ). Polyamines are implicated in both normal brain function and neuropathology, but their specific roles are poorly defined. The major physiological polyamines are PUT, SPM, and SPD, derived from L-ornithine, a product of arginine degradation through activity of ODC, an enzyme expressed abundantly in neuronal and nonneuronal cells (Pegg and McCann, antibody (a-tubulin) showed that (1) in undifferentiated cells with low transglutaminase activity and TG2 protein levels, <10% of total tubulin was cold stable, with no cold/Ca 2+ -stable tubulin; (2) in fully differentiated cells where both transglutaminase activity and TG2 proteins level peaked, the cold-stable tubulin level increased significantly to >40% of total tubulin and cold/Ca 2+ -stable tubulin was >20% of total tubulin); (3) in differentiated cells treated with IR072 where transglutaminase activity was significantly reduced, cold/Ca 2 -stable tubulin was dramatically lowered, to <10%. This suggests a strong correlation between transglutaminase activity and microtubule stability, both of which may contribute to neurite development.
Neuron
Stable Axonal Microtubules and Transglutaminase 1988) . SPD and SPM are produced by enzymatic addition of propylamine from S-adenosylmethionine to PUT and SPD, respectively. High levels of polyamine in brain and rapid changes in ODC expression in response to various stimuli suggest that polyamine levels are well regulated.
Transglutaminases are a family of enzymes activated by Ca 2+ that can catalyze crosslinking of peptides and proteins by formation of g-glutamyl-ε-lysyl bonds (Griffin et al., 2002) . However, in the presence of poly/di/monoamines, transglutaminases catalyze formation of g-glutamyl amine bonds (Folk et al., 1980) . There are eight transglutaminase genes in human and mouse genomes, including secreted and intracellular forms (Esposito and Caputo, 2005) . TG4 and Factor XIII are typically secreted and may contribute to extracellular functions, including having a role in blood clotting. Modification of neuronal cytoskeletal elements requires an intracellular tissue-type transglutaminase. TG1, TG2, TG3, TG5, and possibly TG6 are likely to be intracellular. Intracellular transglutaminase functions are not well understood, but are assumed to modify or crosslink proteins. TG2 is the primary intracellular tissue-type isoform in brain (Cooper et al., 2002) . TG2 activity is found in mammalian CNS and PNS (Hand et al., 1993) . Two features of brain transglutaminase are noteworthy: (1) brain transglutaminase activity increases during development and is linked to neuronal differentiation and neurite outgrowth; and (2) neuronal cytoskeletal elements are in vitro substrates of tissue-type transglutaminase from guinea pig liver (Miller and Anderton, 1986; Selkoe et al., 1982) . The questions of whether these proteins, particularly tubulin, are indeed physiological substrates of brain transglutaminase, and whether modified tubulin changes cytoskeletal properties, remain to be addressed.
Eight independent lines of evidence support the idea that polyamination of neuronal tubulin by transglutaminase contributes to MT stability (see model in Figure S6 ). First, lowering endogenous polyamine levels by inhibiting polyamine synthesis significantly decreases neuronal CST levels (Figure 1 ; Table  S1 ). The simplest interpretation is that decreasing polyamine levels by DFMO reduces polyamination of tubulin and cold/ Ca 2+ -stable MT levels. Decreased polyamine levels may also regulate cold-insoluble tubulin indirectly by decreasing transglutaminase activity, consistent with studies of transglutaminase activity and polyamine levels in other systems (Melino et al., 1988) . Regardless, both mechanisms suggest that polyamination of tubulin plays a role in stabilizing axonal MTs.
Second, radioactive polyamines incorporated into protein are delivered into axons with slow axonal transport of MTs (SCa). Radiolabeled polyamines fractionate with stable MTs through biochemical manipulations, migrate in SDS-PAGE with tubulin, In WT controls, brain TG2 was expressed at similar levels in both age groups, but spinal cord TG2 levels dropped at 5 months relative to those observed in 5 week mice. (B) Transglutaminase activity was significantly reduced in TG2 KO mouse brains compared with age-matched WT mouse brains. Brain transglutaminase activities were similar between the two ages, paralleling TG2 protein levels. (C) Spinal cord transglutaminase activity was much lower in TG2 KO mice than in WT mice at 5 weeks, but transglutaminase activity was comparable in 5 month TG2 KO and coelute with tubulin-immunoreactive protein in gel filtration chromatography (Figure 2) . Third, transglutaminase modifies purified brain tubulin, polymerized MTs, and taxol-stabilized MTs in vitro by covalent addition of polyamines (Figure 3 ). Both fluorescent analogs of polyamines (MDC) and physiological polyamines (SPM and SPD) can be linked to tubulin. MTs containing tubulins polyaminated by endogenous brain transglutaminase match endogenous CST in two key respects: they are resistant to cold/Ca 2+ treatments that normally depolymerize MTs, and they exhibit increased positive charge (Figures 5 and S2) . Although transglutaminase can stabilize substrates through inter-or intramolecular crosslinking (Esposito and Caputo, 2005) , and intermolecular crosslinks can be generated in vitro, crosslinked tubulin is almost exclusively soluble ( Figure 3D ) and does not polymerize (Figure 3F) , whereas polyaminated tubulin polymerizes into MTs that are similar to stable MTs in vivo. Little tubulin crosslinking is observed with physiological levels of polyamines. Polyamination of tubulin occurs on either free tubulins or preassembled MTs. Modification of soluble tubulin dimers may enhance polymerization by generating nucleating seeds, and modification of assembled MTs may increase stability.
Fourth, both a-and b-tubulins have conserved polyamination sites. A prominent modification is the conserved Q15 of b-tubulin, positioned where it may affect GTP hydrolysis by tubulin. Mass spectrometry identified additional modification sites largely on interfaces where a/b-tubulin dimers interact during polymerization. All identified locations are consistent with a role in facilitating and/or stabilizing MT formation.
Fifth, cold stable tubulin is a hallmark of nervous tissue; with little or none detectable in nonneuronal tissues (Figure 6 ). In vivo transglutaminase activity and TG2 protein levels correlate with stable MT levels in nervous tissues. Axonal MTs (e.g., optic and sciatic nerve) are enriched in cold/Ca 2+ -insoluble tubulins, and axon tracts exhibit a higher transglutaminase activity. Fractionation of different neuronal tissues reveals elevated transglutaminase activity in both optic and sciatic nerve ( Figure 6 ). The spatial correlation between neuronal tubulin stability and transglutaminase activity is consistent with a functional role for polyaminated tubulins in axons. Curiously, transglutaminase activity was comparable in both CNS and PNS axon-rich regions, but TG2 protein level was much higher in optic than in sciatic nerve. Although TG2 is the major tissue-type transglutaminase isoform in brain (Ruan and Johnson, 2007) , other tissue-type transglutaminases may contribute to transglutaminase activity in the PNS. Sixth, inhibiting transglutaminase activity reduces MT stability significantly in culture and inhibits neurite outgrowth in differentiating neuroblastoma cells (Figure 7) . Although transglutaminase activity and stable MT levels are relatively low in immature cells, they increase concurrently with differentiation, facilitating extension and stabilization of neurites. This suggests that polyamination of tubulins by transglutaminase is involved in neuronal -stable tubulin levels are 45% and 25%, respectively, of total tubulin at 10 days. At 3 weeks, cold-stable tubulin increased to 58% of total tubulin, of which cold/Ca 2+ -stable tubulin was 32%. At 3 months, cold-stable tubulin increased to 64%, while cold/Ca 2+ -stable tubulin increased to 36%. Differences are statistically significant (**p < 0.001 between 10 day and 3 week groups, *p < 0.05 between 3 week and 3 month groups, n = 6). Error bars indicate ±SEM. differentiation and neurite development. The reorganization of cytoskeletal structures during this process may be modulated by tubulin polyamination, which may nucleate new microtubules and stabilize polymerized MTs.
Seventh, brain and spinal cord from TG2 KO mice have reduced MT stability, consistent with lower transglutaminase activity and absence of TG2 (Figure 8 ). MT stability was significantly reduced where there was a drop in transglutaminase activity, e.g., in 5 week and 5 month TG2 KO brains and in 5 week TG2 KO spinal cords. However, MT stability remains high in regions where transglutaminase activity is not significantly reduced. Thus, MT stability and transglutaminase activity were comparable in 5 month spinal cord for both TG2 KO and WT mice, although TG2 immunoreactivity was eliminated in TG2 KO. Maintenance of transglutaminase activity without detectable TG2 in TG2 KO mice suggests involvement of other transglutaminases in stabilizing MTs in spinal cord and, to a lesser extent, in brain. Thus, cold/Ca 2+ -insoluble tubulin levels were reduced but not eliminated in TG2 KO mice. Identifying transglutaminase isoforms responsible for transglutaminase activity in TG2 KO brain and WT spinal cord requires further study. Regardless, correlations between transglutaminase activity and MT stability in WT and TG2 KO mouse models are consistent with our hypothesis that transglutaminase activity is a major contributor to stable MT formation in vivo.
Eighth, transglutaminase activity and TG2 protein levels correlate with MT stability during development and maturation in vivo. As axons mature and neuronal connections stabilize in response to various postnatal modifiers, such as myelination, cold/Ca 2+ -insoluble tubulin levels increase (Kirkpatrick and Brady, 1994; Kirkpatrick et al., 2001) . Correspondingly, transglutaminase protein levels and enzymatic activity are elevated (Figure 9 ). This suggests that developmental regulation of transglutaminase contributes to MT stabilization as the brain matures.
The role for transglutaminase activity and polyamines in stabilization of axonal MTs does not preclude their playing other roles in the nervous system. Transglutaminases are proposed to be involved in neuronal development (Bailey and Johnson, 2004; Maccioni and Seeds, 1986; Mahoney et al., 2000; Tucholski et al., 2001 ) and signaling (Basso et al., 2012; Dai et al., 2008; Facchiano et al., 2010) , as well as in neurodegenerative diseases (Bailey et al., 2005; Basso et al., 2012; De Vivo et al., 2009; Ruan and Johnson, 2007) .
Transglutaminase activity and polyamine levels correlate with brain maturation, neuronal differentiation, and formation of neurites (Bailey and Johnson, 2004) , but the underlying mechanisms are unclear. Here we propose that a key pathway for regulating neuronal development is modulation of MT stability by TG2-catalyzed polyamination of tubulins. Increases in both TG2 protein and transglutaminase activity increased stable MTs in postnatal brains (Figure 9 ), concurrent with myelination and stabilization of neuronal circuitry. Molecular pathways responsible for effects of myelination on TG2 protein level and transglutaminase activity are under investigation. Transglutaminase activity may also contribute to changes in cellular morphology (Gentile et al., 1992) . Depletion of polyamines results in the disappearance of actin and MT bundles (Pohjanpelto et al., 1981) . Inhibition of polyamine biosynthesis results in defects of neuronal morphogenesis, whereas exogenous polyamines stimulate adult neurogenesis (Malaterre et al., 2004) . All these are consistent with our findings and suggest a common pathway based in part on alteration of MT dynamics and stability through polyamination of tubulin by TG2.
Stabilizing MTs by transglutaminase and polyamines has many positive aspects for normal cytoskeletal structure and function in developing brain, but may be a double-edged sword in the aging nervous system. Transglutaminase activity and polyamine levels increase in the aging brain (Lesort et al., 2000; Slotkin and Bartolome, 1986) and are associated with neurodegenerative diseases including Huntington's (HD), Alzheimer's, and Parkinson's diseases (Jeitner et al., 2009; Lesort et al., 2000) . Functional consequences of these increases may be complex. For example, exogenous polyamines and transglutaminase can be either neuroprotective or neurotoxic depending on dose and context. Similarly, changes in MT stability may be beneficial or detrimental depending on level and circumstance. Stable MTs correlate positively with neuronal stability but negatively with neuronal plasticity. The stable-MT fraction is modest but crucial in early development, facilitating axon growth and plasticity. As neurons mature, MT stability increases and neuronal plasticity decreases. As a consequence, neuronal connectivity may be stabilized, maintaining neuronal architecture, but continued declines in plasticity in aging may limit axonal recovery following injury or in neurodegenerative diseases by limiting MT dynamics. For example, inhibiting transglutaminase in models of HD resulted in a modest improvement of lifespan and behavior in HD mouse models. Although transglutaminase may not be a direct component of molecular pathogenesis in HD, it may compromise the ability of neurons to respond to pathological changes by limiting sprouting and formation of new connections. Understanding changes in cytoskeletal dynamics and stability in development and neurodegeneration, including but not limited to regulation of MT stability, will greatly expand our knowledge of the MT cytoskeleton in health and disease.
EXPERIMENTAL PROCEDURES
All chemicals used were American Chemical Society quality or better, from Sigma, Invitrogen, CalBiochem, or Polysciences. Animals used include Sprague/Dawley rats (200-225 g, Harlan), male C57BL/6 (Jackson Laboratories) and TG2 KO mice (Nanda et al., 2001) . Axonal transport in rat optic nerve was labeled by intravitreal injection of 35 S-methionine or polyamines ( 3 H or 14 C-PUT), as described previously (Brady and Lasek, 1982 ). An injection-sacrifice interval (ISI) of 21 days positioned the SCa wave containing stable and labile MTs in the optic nerve. Radioactive proteins were analyzed by SDS-PAGE and fluorography (Kirkpatrick et al., 2001 ). Our standard protocol for cold/Ca 2+ fractionation of neuronal tubulins was used (Brady et al., 1984) (Figure 1 ; Supplemental Information). Following cold/Ca 2+ fractionation, samples were separated on gradient gels as described and transferred to Immobilon-P membrane (Millipore). Primary antibodies include DM1A (1:20,000, Sigma) for a-tubulin, TGMO1 (1:4000) for TG2, H2 (1:50,000) (Pfister et al., 1989) for kinesin heavy chain, Tu27 (1:10,000, provided by Dr. A. Frankfurter [Caceres et al., 1984] ) for b-tubulin, A2066 (1:5000, Sigma) for b-actin, and pab0022 and pab0023 (1:1200, Covalab) for SPM/SPD. For quantitative immunoblots, the secondary antibody was rat anti-mouse IgG (1:1000, Jackson) detected with 125 I-Protein A and measured by PhosphorImager (Molecular Dynamics) for quantitation with ImageQuant. For fluorescent quantitative immunoblots imaged by Typhoon 9410 (GE Healthcare), secondary antibodies were Cy5-anti-rat (1:400, Jackson) for TG MO1, Cy5-anti-rabbit (1:400, Invitrogen) for pab022 and pab023, and Cy3-antimouse (1:400, Jackson) for the rest.
All studies involving rats or mice were conducted under protocols approved by the appropriate institutional animal care and use committees. All protocols follow established institutional and NIH guidelines for the care and use of vertebrate animals. Difluoromethylornithine (Merrell Dow) was administered as a 2% solution in drinking water. DFMO was given to rats 16-18 hr prior to labeling of axonal transport with 35 S-methionine, and continued for 48 hr, 7 days, or all 21 days of a 21-day ISI. Control rats did not receive DFMO.
To lower endogenous polyamine levels and facilitate protein labeling with labeled PUT ( 14 C or 3 H), DFMO was given 16-18 hr prior to labeling. Following a 21-to 60-day ISI, rats were sacrificed and the optic nerve-optic tract removed for cold/Ca 2+ fractionation. P2 fractions were resuspended in 8 M urea and run on a 60 ml Toyopearl HW-55F (Supelco) column equilibrated in 6 M guanidine-HCL in 100 mM MES (pH 6.8). Total a-tubulin was detected with DM1A. Tubulin was purified from mouse brains through two cycles of polymerization, as described (Castoldi and Popov, 2003) . For polymerized MTs, tubulin (50 mM) was incubated in BR buffer 1980 (BRB80) supplemented with 2 mM GTP at 37 C for 30 min. For Taxol stabilization, taxol was added stepwise equimolar to tubulin in warm BRB80 buffer supplemented with 1 mM dithiothreitol (DTT) and 1 mM GTP and incubated at 37 C for 30 min. Polymerized MTs were pelleted over a glycerol/BRB80 cushion (http://mitchison.med.harvard.edu/ protocols.html).
In vitro polyamination assays used N,N 0 -dimethylcasein or tubulin/MTs as a transglutaminase substrate; with MDC or a polyamine mix (SPM/SPD); and guinea pig transglutaminase (similar to TG2 in brain) in reaction buffer (pH 7.5) ± 10 mM Ca 2+ at 37 C for 60 min. Reactions were stopped by 20 mM cystamine and analyzed by SDS-PAGE. Fluorescence due to MDC incorporation into tubulin was detected by Gel Doc 2000 (Bio-Rad). For endogenous transglutaminase activity assays, transglutaminase extract (150 mg) was incubated with 0.2 mg/ml N,N-dimethylcasein, 4 mM MDC, 5 mM DTT in Tris-HCl-based reaction buffer (pH 7.5) with 10 mM Ca 2+ at 37 C for 60 min. Transglutaminase extracts were prepared from mouse brain by homogenization in 50 mM cold Tris-HCl, 1 mM EDTA, 0.25 M sucrose, 0.4 mM DTT, and protease inhibitor cocktail (Sigma).
Homogenates were centrifuged at 16,000 g at 4 C for 20 min. Pellets were discarded and the supernatant centrifuged at 100,000 g at 4 C for 1 hr to produce the endogenous transglutaminase extract containing transglutaminase, soluble tubulins, and polyamines. A tubulin pellet obtained by centrifugation after stopping polyamination by cystamine was subjected to cold/Ca 2+ fractionation. Polyaminated and native tubulins were analyzed in 2D PAGE after solubilization in 8 M urea, 4% CHAPS, 65 mM DTE, 0.5% ampholytes, and bromophenol blue. Protein solution was cleared and absorbed onto a 7 cm immobilized pH gradient pH 3-10 IPG strip (GE Bioscience) and run for 60 kVhr at room temperature. Before SDS-PAGE, IPG strips were equilibrated and transferred to the top of 4%-12% Nu-Page gels held in position with 0.5% agarose.
In vitro polyaminated tubulins were prepared fresh with MDC, PUT, SPM, or SPD and digested overnight with trypsin; unmodified tubulin was used as a control. Samples were analyzed by LC-MS-MS (Thermo LTQ-FT Ultra) using Agilent Zorbax SB300-C18 0.075 mm ID 3 150 mm capillary analytical column with 0.3 mm ID 3 5 mm Zorbax SB300 C18 trapping 250 nL/min gradient, 5%-65% acetonitrile. Nano ESI Positive Ion mode (resolution 50,000 @m/z 400, Scan 400-1800 m/z) was performed. The top three +2 and greater charged ions for MS/MS from each MS scan were selected. Putative modified peptides were picked based on mass shift in MS1, and specific modification sites were evaluated in MS2 spectra and confirmed through target runs. Searches using MASCOT (version 2.2.04, Matrix Sciences) and MassMatrix search engines against the SwissProtKB using mouse, carbamidomethylation, and methionine oxidation as variable modifications in addition to PUT, SPM, and SPD as variable modifications of Q. Searches were performed using 10 ppm peptide tolerance and 0.6 Da fragment tolerance with decoy database searches to keep false discovery rates below 5%. Synthesis and purification of TG2 selective irreversible inhibitor, IR072 ( Figure S5 ), was as described previously (Chabot et al., 2010) using Fmoc chemistry for solid-phase peptide synthesis. Details of synthesis and characterization of IR072 are given in the Supplemental Experimental Procedures.
For cell culture, SH-SY5Y cells (from ATCC) were grown in DMEM F12 medium (GIBCO) supplemented with 10% FBS, PenStrep, and 2 mM glutamax. To produce a neuronal phenotype, cells were plated on polylysinecoated wells or coverslips to 60% confluency. Differentiation was induced by (1) 10 mM retinoic acid in 2% FBS for 2 days followed by 10 mM retinoic acid in serum-free medium for 3 days; (2) 50 ng/ml BDNF in serum-free medium for 5 days (Szebenyi et al., 2003) . To test the role of transglutaminase in differentiation and neurite outgrowth, cells were treated with the TG2 inhibitor IR072 at 10 mM in media during differentiation. Neurite outgrowth assays were a modification of previously described methods (Szebenyi et al., 2003; see Supplemental Experimental Procedures) . Statistical significance was determined by a paired sample t test.
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